SBBP
STRONGBRIDGE BIOPHARMA PLC
STRONGBRIDGE BIOPHARMA PLC historical holders
total: 1
Fairfax Financial Holdings STRONGBRIDGE BIOPHARMA PLC transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2021 Q2
- Held for:
- 2 quarters
- Latest activity:
- 2021 Q4
Prem Watsa has been an institutional investor in STRONGBRIDGE BIOPHARMA PLC (SBBP) since 2021 Q2. According to 2026 Q1 report, Prem Watsa doesn't hold any shares. The fund/company first acquired SBBP in 2021 Q2, initially purchasing 193,107 shares. Since the initial investment, Fairfax Financial Holdings has made 1 more transaction in this position.
When did Prem Watsa exit their SBBP position?
Prem Watsa no longer holds STRONGBRIDGE BIOPHARMA PLC (SBBP). They sold off their entire position in 2021 Q4, closing out an investment that began in 2021 Q2.
When did Prem Watsa first invest in SBBP?
Prem Watsa first invested in STRONGBRIDGE BIOPHARMA PLC (SBBP) in 2021 Q2 at the reported quarter-end price of $2.96 per share, acquiring 193,107 shares in their initial purchase.
What is Prem Watsa's average cost basis for SBBP?
Based on historical transaction data, Prem Watsa's estimated cost basis for STRONGBRIDGE BIOPHARMA PLC (SBBP) is approximately $2.96 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $2.96
- Weighted AVG sell price:
- $2.03
SBBP transactions history by Fairfax Financial Holdings
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q4
|
0.00%
|
0
|
$2.03
|
|
-100% (-193,107)
|
-0.01%
|
|
2021 Q2
|
0.02%
|
193,107
|
$2.96
|
$572,000
|
new
|
+0.02%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.